MedPath

Non-Interventional Observational Study With Viramune Plus Antiretroviral in HIV Infected Patients

Completed
Conditions
HIV Infections
Registration Number
NCT00876733
Lead Sponsor
Boehringer Ingelheim
Brief Summary

This observational study is supposed to assess (under conditions of clinical practice in daily routine) whether treatment with Viramune (nevirapine) in combination with ARV, e.g. Combivir (Zidovudine and Lamivudine), Kivexa (Abacavir and Lamivudine) or Truvada (tenofovir and emtricitabine) will durably suppress viral load below the limit of detection or will maintain suppression of viral replication (HIV-RNA below limit of detection) achieved under previous anti-retroviral combination therapy after switch to combination treatment of Viramune (nevirapine) and ARV, e.g. Combivir (Zidovudine and Lamivudine), Kivexa (Abacavir and Lamivudine) or Truvada (tenofovir and emtricitabine).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
605
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Number of Participants With Treatment Emergent Adverse Events (AE) and All Serious AEs36 months

Number of participants with Treatment Emergent Adverse Events (AE) and All Serious AEs

Secondary Outcome Measures
NameTimeMethod
Changes in the Laboratory Data (Total Cholesterol) After 36 Months From BaselineBaseline and 36 months

The changes in the laboratory data (Total Cholesterol) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.

Changes in the Laboratory Data (Total Cholesterol) After 12 Months From BaselineBaseline and 12 months

The changes in the laboratory data (Total Cholesterol) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.

Changes in the Laboratory Data (LDL Cholesterol) After 12 Months From BaselineBaseline and 12 months

The changes in the laboratory data ( Low density protein (LDL) Cholesterol) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.

Changes in the Viral Load After 36 Months From Baseline.Baseline and 36 months

The change in the log10 viral load from baseline after 36 months was calculated by subtracting the baseline value from the value after 36 months. Therefore, a negative change represents a decrease in viral load.

Changes in the Laboratory Data (AST) After 12 Months From BaselineBaseline and 12 months

The changes in the laboratory data (Aspartate transminase (AST)) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.

Changes in the Laboratory Data (LDL Cholesterol) After 36 Months From BaselineBaseline and 36 months

The changes in the laboratory data ( Low density protein (LDL) Cholesterol) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.

Changes in the Laboratory Data (Blood Glucose) After 36 Months From BaselineBaseline and 36 months

The changes in the laboratory data (Blood Glucose) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.

Changes in the Viral Load After 12 Months From Baseline.Baseline and 12 months

The change in the log10 viral load from baseline after 12 months was calculated by subtracting the baseline value from the value after 12 months. Therefore, a negative change represents a decrease in viral load.

Changes in the Cluster of Differentiation 4 (CD4+) Cell Count After 12 Months From Baseline.Baseline and 12 months

The change in the CD4+ cell count from baseline after 12 months was calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase in CD4+ cell count.

Changes in the Laboratory Data (HDL Cholesterol) After 12 Months From BaselineBaseline and 12 months

The changes in the laboratory data ( High density protein (HDL) Cholesterol) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.

Changes in the Laboratory Data (Blood Glucose) After 12 Months From BaselineBaseline and 12 months

The changes in the laboratory data (Blood Glucose) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.

Changes in the Laboratory Data (Haemoglobin) After 12 Months From BaselineBaseline and 12 months

The changes in the laboratory data (Haemoglobin) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.

Changes in the CD4+ Cell Count After 36 Months From Baseline.Baseline and 36 months

The change in the CD4+ cell count from baseline after 36 months was calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase in CD4+ cell count.

Changes in the Laboratory Data (Triglycerides) After 12 Months From BaselineBaseline and 12 months

The changes in the laboratory data (Triglycerides) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.

Changes in the Laboratory Data (ALT) After 12 Months From BaselineBaseline and 12 months

The changes in the laboratory data (Alanine transaminase (ALT)) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.

Changes in the Laboratory Data (Gamma GT) After 12 Months From BaselineBaseline and 12 months

The changes in the laboratory data (Gamma glutamyl transferase (Gamma GT)) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.

Changes in the Laboratory Data (Creatinine) After 12 Months From BaselineBaseline and 12 months

The changes in the laboratory data (Creatinine) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.

Changes in the Laboratory Data (Triglycerides) After 36 Months From BaselineBaseline and 36 months

The changes in the laboratory data (Triglycerides) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.

Changes in the Laboratory Data (AST) After 36 Months From BaselineBaseline and 36 months

The changes in the laboratory data (Aspartate transminase (AST)) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.

Changes in the Laboratory Data (Creatinine) After 36 Months From BaselineBaseline and 36 months

The changes in the laboratory data (Creatinine) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.

Changes in the Laboratory Data (HDL Cholesterol) After 36 Months From BaselineBaseline and 36 months

The changes in the laboratory data ( High density protein (HDL) Cholesterol) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.

Changes in the Laboratory Data (Gamma GT) After 36 Months From BaselineBaseline and 36 months

The changes in the laboratory data (Gamma glutamyl transferase (Gamma GT)) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.

Changes in the Laboratory Data (ALT) After 36 Months From BaselineBaseline and 36 months

The changes in the laboratory data (Alanine transaminase (ALT)) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.

Changes in the Laboratory Data (Haemoglobin) After 36 Months From BaselineBaseline and 36 months

The changes in the laboratory data (Haemoglobin) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.

Trial Locations

Locations (66)

Boehringer Ingelheim Investigational Site 14

🇩🇪

Aachen, Germany

Boehringer Ingelheim Investigational Site 12

🇩🇪

Berlin, Germany

Boehringer Ingelheim Investigational Site 13

🇩🇪

Berlin, Germany

Boehringer Ingelheim Investigational Site 15

🇩🇪

Berlin, Germany

Boehringer Ingelheim Investigational Site 19

🇩🇪

Berlin, Germany

Boehringer Ingelheim Investigational Site 21

🇩🇪

Berlin, Germany

Boehringer Ingelheim Investigational Site 23

🇩🇪

Berlin, Germany

Boehringer Ingelheim Investigational Site 24

🇩🇪

Berlin, Germany

Boehringer Ingelheim Investigational Site 28

🇩🇪

Berlin, Germany

Boehringer Ingelheim Investigational Site 30

🇩🇪

Berlin, Germany

Scroll for more (56 remaining)
Boehringer Ingelheim Investigational Site 14
🇩🇪Aachen, Germany

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.